Key result
Exogenous GH reduces hepatic steatosis and inflammation in mice via CD36 downregulation, without affecting atherosclerosis.
Why the study?
The effect of growth hormone treatment on metabolic disorders including atherosclerosis, hepatic steatosis, and obesity has not been well characterized.
Does exogenous growth hormone injection reduce atherosclerosis and hepatic steatosis in Western diet-fed Ldlr−/− mice?
Does exogenous growth hormone injection reduce atherosclerosis and hepatic steatosis in Western diet-fed Ldlr−/− mice?
In a hyperlipidemic mouse model, growth hormone treatment attenuates hepatic steatosis and inflammation via CD36 downregulation without affecting atherosclerosis.
Hypothesis-generating for GH in hyperlipidemic steatohepatitis; leaves open human translation and atherosclerosis effects.
The recombinant human growth hormone (GH) has been used for the treatment of growth hormone deficiency (GHD) and diverse short stature state, and its physiological and therapeutic effects are well documented. However, since the effect of GH treatment on metabolic disorders has not been well characterized, we injected GH to Western diet-fed low-density lipoprotein receptor-deficient (Ldlr−/−) mice to understand the exact effect of GH on metabolic diseases including atherosclerosis, hepatic steatosis, and obesity. Exogenous GH treatment increased plasma IGF-1 concentration and decreased body weight without affecting serum lipid profiles. GH treatment changed neither atherosclerotic lesion size nor collagen and smooth muscle cells accumulation in the lesion. GH treatment reduced macrophage accumulation in adipose tissue. Importantly, GH treatment attenuated hepatic steatosis and inflammation. The hepatic expression IL-1β mRNA were decreased by GH treatment. The mRNA and protein levels of CD36 were markedly decreased in GH treated mice without significant changes in other molecules related to lipid metabolism. Therefore, the treatment of GH treatment could attenuate hepatic steatosis and inflammation with downregulation of CD36 expression in hyperlipidemic condition.
No takes yet. Share an insight, caveat, or question.
Jang et al. (2020) studied Hepatic steatosis and metabolic diseases. Growth hormone (GH) was evaluated on Hepatic steatosis, inflammation, and atherosclerosis. Exogenous growth hormone treatment attenuated hepatic steatosis and inflammation in Western diet-fed Ldlr−/− mice via downregulation of hepatic CD36 expression, without affecting atherosclerosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: